癌细胞和免疫系统之间的相互作用对于癌症的进展和治疗至关重要。在这方面，以全身炎症标志物和TIL为标志的肿瘤免疫微环境和宏观环境可以被认为是肿瘤（包括口腔鳞状细胞癌和肺鳞状细胞癌）的关键预后因素。我们对口腔鳞状细胞癌患者进行了回顾性临床研究（ OSCC）和肺鳞状细胞癌（LUSCC），检查分期、合并症、治疗和结果。我们评估了术前全身炎症标志物和肿瘤微环境组成的预后意义。发现全身炎症标志物（NLR、MLR 和 PLR）与肿瘤微环境因素（例如 TIL 和 CD8 细胞流行率升高的炎症标志物）之间存在关联。高级阶段。具体而言，NLR 在 OSCC 中具有预后作用，而 PLR 在 LUSCC 中具有预后作用。使用截止值，我们将肿瘤样本分为两个预后组。此外，肿瘤基质的 TIL 水平 > 15% 与 OSCC 和 LUSCC 的总生存期延长相关，而 CD8 表达增加与 LUSCC 的无病生存期延长相关。全身炎症标志物和 TIL 可能是有价值的生存预后因素，强调免疫反应在 OSCC 和 LUSCC 中的作用。尽管由于缺乏标准化，所提出的队列的临床整合有限，但我们得出的结论是，分析肿瘤免疫谱可能提供新的预后见解。未来整合到癌症分类中可以改善风险分层和治疗指导。

The interplay between cancer cells and the immune system is crucial in cancer progression and treatment. In this regard, the tumor immune microenvironment and macroenvironment, marked by systemic inflammation markers and TILs, could be considered key prognostic factors in tumors, including oral and lung squamous cell carcinoma.We conducted a retrospective clinical study on patients with Oral Squamous Cell Carcinoma (OSCC) and Lung Squamous Cell Carcinoma (LUSCC), examining stages, comorbidities, treatments, and outcomes. We evaluated the prognostic significance of pre-surgical systemic inflammation markers and tumor microenvironment composition.Associations were found between systemic inflammation markers-NLR, MLR, and PLR-and tumor microenvironment factors, such as TILs and CD8+ cell prevalence-elevated inflammation markers correlated with advanced stages. Specifically, NLR was prognostic in OSCC, whereas PLR was prognostic in LUSCC. Using a cutoff value, we divided our tumor samples into two prognostic groups. Moreover, TILs levels >15% of tumor stroma correlated with prolonged overall survival in both OSCC and LUSCC, while increased CD8+ expression was linked to extended disease-free survival in LUSCC.Systemic inflammation markers and TILs can be valuable prognostic factors of survival, highlighting the immune response's role in OSCC and LUSCC. Despite limited clinical integration of the presented cohorts due to a lack of standardization, we concluded that analyzing tumor immune profiles may offer novel prognostic insights.Future integration into cancer classification could improve risk stratification and treatment guidance.